Skip to content

Progressive Stroke Emergency Angioplasty RevascuLarization for IntraCranial Artery Stenosis(PEARL-ICAS)

Efficacy and Safety of Emergency Angioplasty in the Treatment of Progressive Stroke With Severe Intracranial Artery Stenosis: A Multicenter, Prospective, Open-label, Endpoint-Blinded, Randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088214
Enrollment
Unknown
Registered
2024-08-13
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial artery stenosis Progressive ischemic stroke Emergency angioplasty

Interventions

The control group:standard medical management
The experimental group:emergency angioplasty

Sponsors

Shenzhen Hospital of Southern Medical Unversity
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1.Age>= 18 years old; 2.Stroke onset within 14 days; 3.Pre-onset mRS =2 a and an increase in NIHSS >=4 at progression; 5.ASPECTS or pc-ASPECTS >= 6; 6.Imaging demonstrates watershed cerebral infarction or hypoperfusion in the culprit vascular territory; 7.Progressive ischemic stroke caused by severe stenosis (70%-99%, measured according to the WASID criteria) of intracranial large vessels, screened by CTA/MRA and confirmed by DSA, including the intracranial internal carotid artery (C4-C7 segments), the middle cerebral artery (M1 and M2 segments), basilar artery, and V4 segment of the vertebral artery; 8.The patient or the agent signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Diameter of target vessel 185 mmHg or diastolic BP >110 mmHg); 21.Life expectancy <3 months (e.g., terminal illnesses such as malignancy, severe cardiopulmonary disease). 1.Other conditions deemed unsuitable for participation by the investigator (e.g., inability to understand/comply with study procedures/follow-up due to psychiatric disorders, cognitive or emotional impairments).

Design outcomes

Primary

MeasureTime frame
The modified Rankin Scale;

Secondary

MeasureTime frame
Incidence of symptomatic intracranial hemorrhage;NIHSS score;EQ-5D-5L;Incidence of symptomatic intracranial hemorrhage;

Countries

China

Contacts

Public ContactHe XiongJun

Shenzhen Hospital of Southern Medical Unversity

drxjhe@163.com+86 755 23360593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026